An alternative to the gateway hypothesis is the common liability to addiction (CLA) theory. It states that some individuals are, for various reasons, willing to try multiple recreational substances. The "gateway" drugs are merely those that are (usually) available at an earlier age than the harder drugs. Researchers have noted in an extensive review that it is dangerous to present the sequence of events described in gateway "theory" in causative terms as this hinders both research and intervention.
With that stereotype now changing in addition to the outbreak of legal marketplaces in 33 states, we’re seeing a boom in cross-industry trends where major corporate and investment players are starting to enter the cannabis sector or at least signal willingness to do so. These trends are proving so strong that companies are starting to think it’s important to get in the game or risk being left behind later. That’s why major brands are either dipping a toe into the water or laying the groundwork for a cannonball-level splash when the Green Rush finally breaks.
In the 1970s, the taxonomic classification of Cannabis took on added significance in North America. Laws prohibiting Cannabis in the United States and Canada specifically named products of C. sativa as prohibited materials. Enterprising attorneys for the defense in a few drug busts argued that the seized Cannabis material may not have been C. sativa, and was therefore not prohibited by law. Attorneys on both sides recruited botanists to provide expert testimony. Among those testifying for the prosecution was Dr. Ernest Small, while Dr. Richard E. Schultes and others testified for the defense. The botanists engaged in heated debate (outside of court), and both camps impugned the other's integrity. The defense attorneys were not often successful in winning their case, because the intent of the law was clear.
Particular difficulties face the clinician managing intractable patients afflicted with cancer-associated pain, neuropathic pain, and central pain states (eg, pain associated with multiple sclerosis) that are often inadequately treated with available opiates, antidepressants and anticonvulsant drugs. Physicians are seeking new approaches to treatment of these conditions but many remain concerned about increasing governmental scrutiny of their prescribing practices (Fishman 2006), prescription drug abuse or diversion. The entry of cannabinoid medicines to the pharmacopoeia offers a novel approach to the issue of chronic pain management, offering new hope to many, but also stoking the flames of controversy among politicians and the public alike.
The dosages mentioned do not take into account the strength of the tincture. I have Elixinol 300, I took 1/2 dropper (0.5ml, which offers 5mg of CBD) as indicated on the bottle and felt severely nauseous for 3 hours thereafter. There is no way I cold take this dose twice per day, as recommended on the bottle. The high dosages on this site must surely be for much weaker concentrations?
One of the earliest success stories involves a young girl named Charlotte who was given an ingestible oil derived from Charlotte’s Web, a CBD strain that was specifically developed to provide her with all the benefits of the drug without the high. In less than two years, Charlotte went from a monthly seizure count of 1,200 to about three. Other success stories followed and more parents have begun to speak out, particularly parents who are desperate for access to this life-saving treatment.
Still, as the saying goes, absence of evidence isn’t necessarily evidence of absence, and there’s a reason we don’t have a ton of solid research on CBDs yet — “to study it, we need a good source, ” said Ziva Cooper, who is an associate professor at Columbia University and was on the National Academies committee. CBD is hard to get because it’s still technically a Schedule I drug, which limits its availability, Cooper said.
Cannabinoids are divided into three groups. The first are naturally occurring 21-carbon terpenophenolic compounds found to date solely in plants of the Cannabis genus, currently termed phytocannabinoids (Pate 1994). The best known analgesic of these is Δ9-tetrahydrocannabinol (henceforth, THC)(Figure 1), first isolated and synthesized in 1964 (Gaoni and Mechoulam 1964). In plant preparations and whole extracts, its activity is complemented by other “minor” phytocannabinoids such as cannabidiol (CBD) (Figure 1), cannabis terpenoids and flavonoids, as will be discussed subsequently.